Nutriband CEO Gareth Sheridan Named EY Entrepreneur of the Year 2025 Finalist
Nutriband's CEO Gareth Sheridan has been recognized as a finalist in the EY Entrepreneur of the Year Awards, highlighting the company's innovative work in transdermal drug delivery and abuse-deterrent technologies.
Gareth Sheridan, CEO of Nutriband Inc. (NASDAQ: NTRB), has been named a finalist in the Established category of the 2025 EY Entrepreneur of the Year Awards. The recognition underscores the company's significant progress in developing advanced pharmaceutical technologies aimed at addressing critical healthcare challenges.
Sheridan was selected from a competitive pool of 27 Irish entrepreneurs representing 24 companies generating over €1 billion in annual revenue. The nomination reflects his leadership in transforming Nutriband from an early-stage startup to a publicly listed life sciences company focused on innovative drug delivery solutions.
The company's lead product, AVERSA™, represents a breakthrough in pain management technology. Designed to prevent misuse and abuse of opioid patches, AVERSA addresses a significant public health concern surrounding prescription pain medications.
As a finalist, Sheridan will participate in a CEO retreat in Japan and compete for the overall Entrepreneur of the Year title, which will be awarded at a gala event in November. The EY Entrepreneur of the Year Award recognizes outstanding entrepreneurs who demonstrate excellence, innovation, and profound impact in their respective industries.
Nutriband's recognition highlights the growing importance of developing technological solutions that can mitigate potential drug misuse while maintaining effective medical treatment options. The company's approach to creating abuse-deterrent technologies could potentially transform pain management strategies and contribute to addressing the ongoing opioid crisis.